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Host defensekine ligand 9 (CXCL9) in host defense following infection with mouse hepatitis
virus (MHV) was determined. Inoculation of the central nervous system (CNS) of CXCL9−/− mice with MHV
resulted in accelerated and increased mortality compared to wild type mice supporting an important role for
CXCL9 in anti-viral defense. In addition, infection of RAG1−/− or CXCL9−/− mice with a recombinant MHV
expressing CXCL9 (MHV-CXCL9) resulted in protection from disease that correlated with reduced viral titers
within the brain and NK cell-mediated protection in the liver. Survival in MHV-CXCL9-infected CXCL9−/−
mice was associated with reduced viral burden within the brain that coincided with increased T cell
inﬁltration. Similarly, viral clearance from the livers of MHV-CXCL9-infected mice was accelerated but
independent of increased T cell or NK cell inﬁltration. These observations indicate that CXCL9 promotes
protection from coronavirus-induced neurological and liver disease.
© 2008 Elsevier Inc. All rights reserved.IntroductionInoculation of mouse hepatitis virus (MHV, a positive-strand RNA
virus) into the central nervous system (CNS) of susceptible mice
results in an acute encephalomyelitis that is characterized by wide-
spread viral replication primarily in astrocytes, microglia, and
oligodendrocytes (reviewed in Bergmann et al., 2006; Glass et al.,
2002). Chemokines are expressed within the CNS early following
MHV infection and are important in host defense by attracting
activated lymphocytes bearing the appropriate chemokine receptor
which then participate in reduction in viral burden via secretion of
IFN-γ and cytolytic activity (Chen et al., 2001; Liu et al., 2000,
2001a; Parra et al., 1999, 2000). However, viral RNA/antigen often
persists and surviving mice will develop an immune-mediated
demyelinating disease with similar clinical and histologic character-
istics to the human demyelinating disease multiple sclerosis (MS)
(Lane and Buchmeier, 1997; Marten et al., 2001; Templeton and
Perlman, 2007; Weiner, 1973). Secretion of chemokines during
chronic disease ampliﬁes the severity of demyelination in MHV-
infected mice by recruiting activated T cells and macrophages intoHealth grants NS41249 (T.E.L.)
ty Grant 3278-A-3 to T.E.L.
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l rights reserved.the CNS that participate in myelin destruction (Glass et al., 2004; Liu
et al., 2001b).
Early followingMHV infection, the CXC chemokine ligand10 (CXCL10,
also known as IP-10) is expressed primarily by ependymal cells,
astrocytes, and microglia (Lane et al., 1998). CXCL10 aids in defense
during acute disease by attracting antigen-speciﬁc T cells expressing the
receptor CXCR3. Indeed, use of blocking antibodies speciﬁc for either
CXCL10, CXCR3, or infection of CXCL10 deﬁcient mice results in impaired
T cell trafﬁcking into the CNS of MHV-infected mice and delayed viral
clearance (Dufour et al., 2002; Liu et al., 2000; Stiles et al., 2006).
Moreover, CXCL10 expression is also important in enhancing innate
immune responses by attracting NK cells into the CNS which aid in
defense through the secretion of IFN-γ (Triﬁlo et al., 2004). CXCL9 (also
known as MIG, monokine induced by interferon gamma) is a CXC
chemokine that is closely related to CXCL10 with regards to both
structure and function (Farber, 1997). Similar to CXCL10, CXCL9 is
expressed by awide variety of cell types following exposure to cytokines
including IFN-α/β and IFN-γ (Farber, 1997; Ho and Ivashkiv, 2006). In
addition, CXCL9 expression is correlated with host defense following
infection of mice with poxvirus (Mahalingam et al., 1999, 2000), murine
cytomegalovirus (Hokeness et al., 2007; Salazar-Mather et al., 2000),
adenovirus (Arai et al., 2002) and transgenic mice capable of replicating
hepatitis B virus (Kakimi et al., 2001a, 2001b) by attracting CXCR3-
expressing T cells and NK cells to sites of viral infection and replication.
With regards to MHV infection, blocking CXCL9 function by administer-
ing anti-CXCL9 antibodies to infected mice resulted in increased
mortality and enhanced recovery of virus from the brain that correlated
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emphasize an important role for both CXCL9 andCXCL10 in orchestrating
the recruitmentof targetedCXCR3+lymphocytes into theCNS in response
to MHV infection that aid in host defense by reducing viral burden.
The current study was undertaken to further our understanding of
how the chemokine CXCL9 participates in innate immune responses
following MHV infection of the brain and liver as earlier studies from
our laboratory support an important role for chemokines in shaping
host defense in the absence of an adaptive immune response (Triﬁlo etFig. 1. CXCL9 is important in host defense following coronavirus infection. C57BL/6 (CXCL9
survival, viral titers, and CXCL9 production determined. (A) Both CXCL9−/− and RAG1−/− mi
mice. Data shown are representative of two independent experiments with a minimum
determined at days 1, 3, and 5 p.i. with virus. Similar titers were present within the brains an
titers within the brains of RAG1−/−mice compared towild typemice (not signiﬁcant). Viral tit
to the high mortality rate. (C) CXCL9 protein levels within brains and livers of infected wild
detection (BD) within the brains or livers of sham-infected or infected CXCL9−/− mice at
independent experiments with a minimum of three mice per time point.al., 2004). In addition, the ability of mice deﬁcient in CXCL9 (CXCL9−/−
mice) to generate an effective host response in response to MHV
infection was determined. To accomplish these goals, we infected
mice in which CXCL9 expression was genetically silenced (CXCL9−/−
mice) with a recombinant MHV that expresses CXCL9 (MHV-CXCL9)
from a dispensable open reading frame within the viral genome and
infected RAG1−/− and CXCL9−/− mice to evaluate how CXCL9
contributes to anti-viral defenses following MHV infection of the
brain and liver.+/+), RAG1−/−, and CXCL9−/− mice were i.c. infected with 5000 PFU of MHV-A59 and
ce exhibited increased mortality following MHV-A59 infection compared to wild type
of 4 mice per experimental group. (B) Viral titers within the brains and livers were
d livers of experimental mice at days 1 and 3 p.i. while by day 5 p.i. there were elevated
ers in brains and livers of infected CXCL9−/−micewere not determined (ND) at day 5 due
type and RAG1−/−mice were determined by ELISA at days 1 and 3 p.i. CXCL9 was below
days 1 and 3 p.i. Data in B and C are presented as average±SEM and represent two
Fig. 2. Construction of a CXCL9-expressing recombinant of MHV-A59. (A) Construction of a transcription vector for synthesis of donor RNA. Plasmids pCXCL9A and pCXCL9B were
derived in two steps from parent plasmid pMH54 via intermediate constructs (not shown) resulting in the removal of 267 nucleotides (nt) of MHV sequence from pMH54 and
replacement with either CXCL9 sequence in pCXCL9A or inverted CXCL9 sequence in pCXCL9B. Restriction sites shown are those relevant to plasmid construction, runoff in vitro
transcription, or recombinant analysis. The expanded region of the sequence shows the context of either the inserted CXCL9 ORF or the inverted CXCL9 containing several stop codon
sequences. (B) Generation of recombinant viruses. Diagramatic scheme for generation of MHV-A59 CXCL9 or cCXCL9 recombinants by targeted recombination between the parental
virus, thermolabile N gene deletion mutant Alb4, and donor RNA transcribed from either plasmid pCXCL9A or pCXC9B. Recombination events occurring 5′ to the N gene yet 3′ to gene
for (denoted by “a”) will result in generation of WT MHV-A59 genome and will be visualized by large plaques during the screening procedure but fail genetic screening.
Recombination events occurring in the region denoted by “b”will result in reconstitution of MHV containing either CXCL9 or cCXCL9 coding sequence. (C) Recombinant virus growth
kinetics. Conﬂuent monolayers of 17Cl1 cells were infected with either MHV-CXCL9 (black line) or MHV-cCXCL9 (grey line) at a multiplicity of 0.01 per cell. At the indicated times p.i.,
aliquots of medium were removed and plaque titers determined on mouse L2 cells. Data shown are a representative experiment from three separate experiments. (D) CXCL9 ELISA
analysis. ELISA analysis of CXCL9 protein expression from supernatants of infected cells was performed at indicated time points. No CXCL9 protein was detected in supernatants
obtained from cell monolayers infected with MHV-cCXCL9. Results presented are representative of two separate experiments.
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MHV infection of CXCL9−/− and RAG1−/− mice
To determine the importance of CXCL9 in host defense following
MHV infection, CXCL9−/− mice were infected with MHV-A59 and
survival compared to infected wild type C57BL/6 (CXCL9+/+) and
RAG1−/− mice. As shown in Fig. 1A, infection of wild type mice with
MHV-A59 resulted in ∼40% survival by day 12 p.i. In contrast, MHV-
A59 infection of CXCL9−/− mice resulted in increased susceptibility
with 100% of mice dead by day 5 p.i. (Fig. 1A). Similarly, RAG1−/−mice
infected with virus also exhibited increased susceptibility with 100%
of mice dying by day 8 (Fig. 1A). Comparison of viral titers within the
brains and livers of infected mice revealed similar titers at days 1 and
3 p.i. (Fig. 1B). Although there were increased viral titers within the
brains, but not livers, of RAG1−/− at day 5 p.i. compared to wild type
mice, this difference was not signiﬁcant (Fig. 1B). CXCL9 protein was
detected within the brains and livers of infected wild type mice and
RAG1−/− mice at days 1 and 3 p.i. with greater levels present inFig. 3. RAG1−/− mortality following infection. (A) Morality curves for RAG1−/− mice infecte
cCXCL9 exhibited dramatically higher mortality rates with 100% of infected mice dead by day
representative of two separate experiments with a minimum of 6 mice per experimental gr
infected with MHV-CXCL9 compared to mice infected with MHV-cCXCL9 at days 3, 5, and
experiments with a minimum of 4 mice per experimental group.wild type mice at both times points (Fig. 1C). No CXCL9 protein was
detected within tissues of infected CXCL9−/−mice (Fig. 1C). These data
demonstrate the importance of CXCL9 in host defense following MHV
infection of the brain and liver. Presumably, this is the result of
deﬁcient recruitment of cells expressing the CXCL9 receptor CXCR3
e.g. T cells and NK cells into infected tissues that aid in control of
viral replication. Moreover, these data highlight the importance of an
adaptive immune response in controlling MHV replication, particu-
larly within the brain, as RAG1−/− mice also exhibited increased
mortality compared to immunocompetent wild type mice.
Construction and characterization of recombinant viruses
In order to assess the functional contributions of CXCL9 in host
defense following MHV infection, we constructed a recombinant of
MHV capable of expressing CXCL9 with the goal of instilling this virus
into the CNS of either RAG1−/− mice or CXCL9−/− mice and evaluating
disease severity. We inserted the exogenous CXCL9 gene into a
functional transcription unit in the genome of MHV-A59 in place ofd i.c. with either 5000 PFU of MHV-CXCL9 or MHV-cCXCL9. Mice infected with MHV-
9 p.i. while ∼20% of MHV-CXCL9-infected mice remained alive until day 20 p.i. Data are
oup. Viral titers are reduced (⁎p≤0.05) in the brains (B) and livers (C) of RAG1−/− mice
7 p.i. Data are presented as the average±SEM and are representative of two separate
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not essential for replication either in tissue culture or in the mouse
host (Ontiveros et al., 2001; Weiss et al., 1993; Yokomori and Lai,
1991). This has been most clearly shown in the JHM strain of MHV,
where targeted disruption of both transcription and translation of
gene 4 was demonstrated to have no detectable effect on growth in
tissue culture or virulence in the mouse CNS (Ontiveros et al., 2001).
Moreover, in MHV-A59 the expression of gene 4 is abrogated by a
frameshift mutation that truncates the protein after 19 codons (Weiss
et al., 1993). The CXCL9-expressing recombinant of MHV was
generated by targeted RNA recombination, a reverse genetic system
that has been used to manipulate the 31-kb RNA genome of MHVFig. 4. Viral infection of brain and liver in RAG1−/− mice. Representative sagittal sections f
infected with either MHV-cCXCL9 (A and B) or MHV-CXCL9 (C and D). MHV-CXCL9 infection
infectedmice at day 5 p.i. (A). However, comparison of viral antigen localization between infe
thalamus, hypothalamus, and medulla. Moreover, there was no apparent difference in cellu
infected with either MHV-CXCL9 (E) or MHV-cCXCL9 (F). Brains are representative of 4 mice
antigen was detected in the livers of MHV-CXCL9-infected mice (D) compared to MHV-cC
encircling areas of necrotic and focally apoptotic cells (indicated by arrows) that were readily
mice (G). Immunostaining for viral antigen within livers was performed for two separate ex(Koetzner et al., 1992; Masters et al., 1994). To construct recombinants,
the CXCL9 ORF was ﬁrst introduced into plasmid pMH54 (pMH54-
CXCL9) downstream of the gene 4 transcription-regulating sequence
(TRS) and replacing the ﬁrst two-thirds of gene 4 (Fig. 2A). As a
control, a separate pMH54 vector was generated that contained an
inverted CXCL9 ORF (pMH54-cCXCL9) with several engineered stop
codons to ensure that generation of a polypeptide was inhibited (Fig.
2A). Viral recombinants were generated through RNA-RNA recombi-
nation between either pCXCL9A or pCXCL9B-derived synthetic
transcripts and the genome of the N gene deletion mutant Alb4 (Fig.
2B), which was selected against on the basis of its thermolability
(Koetzner et al., 1992; Masters et al., 1994). Independent, plaque-rom brains and livers of mice stained for viral antigen (brown chromagen) from mice
results in reduced staining for viral antigen in the brain (C) compared to MHV-cCXCL9-
ctions displayed similar patterns of infectionwith staining detected in the hippocampus,
lar tropism as viral antigen is readily detected in glial cells within the brains of mice
per group with a minimum of 6 sections/mouse examined. Diminished staining for viral
XCL9-infected mice (B) at day 5 p.i. Viral antigen was detectable within hepatocytes
present in MHV-cCXCL9-infected mice (H) yet relatively absent in MHV-CXCL9-infected
periments with a minimum of 2 mice per group with 6 sections per mouse examined.
Fig. 5. NK cell inﬁltration into brains and livers. (A) Total numbers of NK cells (NK1.1+)
inﬁltrating into the brains and livers of RAG1−/− mice infected with either MHV-CXCL9
or MHV-cCXCL9. NK cells were elevated (⁎p≤0.05) in the livers of mice infected with
MHV-CXCL9 at day 3 p.i. compared to MHV-cCXCL9-infected mice. (B) RAG1−/− mice
were infected with MHV-CXCL9 and treated with anti-asialo GM1 antisera to deplete
NK cells. Such treatment resulted in a signiﬁcant reduction (⁎p≤0.05) of NK cells within
the brains and livers of infectedmice at days 2 and 5 p.i. (C) Depletion of NK cells did not
affect viral titers within the brain but resulted in increased viral titers (⁎p≤0.05) within
the livers at days 2 and 5 p.i. Results are presented as average ± SEM and represent two
separate experiments with a minimum of three mice per time point.
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analysis of viral RNA, and the integrity of the CXCL9 ORF or the
control CXCL9 (cCXCL9) were ascertained by direct sequencing of
puriﬁed PCR products. One CXCL9 recombinant virus (MHV-CXCL9)
and a control CXCL9 (MHV-cCXCL9) were chosen for subsequent
experiments in mice. Both MHV-CXCL9 and MHV-cCXCL9 formed
plaques of indistinguishable size and morphology in tissue culture,
and both viruses grew to high titers, producing comparable amounts
of syncytia and cytopathic effect in infected cells. To directly compare
the two recombinants, we separately infected monolayers with either
MHV-CXCL9 or MHV-cCXCL9 and determined the infectious titer of
virus released at various times from 2 to 48 h p.i. This revealed that the
growth kinetics of the CXCL9 recombinant and the control counterpart
were indistinguishable (Fig. 2C). To ascertain whether CXCL9 was
capable of being secreted by the engineered recombinant virus,
supernatants from mock-infected cells or from cells infected with
either MHV-CXCL9 or MHV-cCXCL9 were analyzed by ELISA. The
results shown in Fig. 2D reveal increased expression of CXCL9 protein
at 12 and 24 h from MHV-CXCL9-infected cultures. No CXCL9 was
detected within supernatants of cultures following infection with
MHV-cCXCL9 (sensitivity of assayb10 pg/mL).
Intracerebral inoculation of RAG1−/− mice with recombinant viruses
We next determined if RAG1−/− mice were protected from disease
following infection with MHV-CXCL9. As shown in Fig. 3A, RAG1−/−
mice infected with MHV-cCXCL9 resulted in death as early as 5 days
p.i. and 100% mortality by day 9 p.i. In contrast, MHV-CXCL9-infected
mice displayed 100% survival up to 14 days p.i. following infection
and ∼20% of mice survived until 20 days p.i. Correlating with the
increased mortality in mice infected with MHV-cCXCL9, there was a
signiﬁcant increase (p≤0.05) in viral titers within the brains at days 3,
5, and 7 p.i. as compared to MHV-CXCL9-infected mice (Fig. 3B). In
addition, viral titers were reduced within the livers of MHV-CXCL9-
infected mice compared to MHV-cCXCL9-infected mice at days 3, 5,
and 7 p.i. (Fig. 3C). The enhanced ability to control viral replication
within both the brain and livers of MHV-CXCL9-infected mice was not
the result of increased IFN-γ secretion as there were no differences in
IFN-γ protein levels within the brains as determined by ELISA nor
increased expression of MHC class II staining on microglia (data not
shown). Immunohistochemical staining supported titer data from
brains and livers demonstrating that diminished survival was
associated with increased viral antigen within the brain (Fig. 4A)
and liver (Fig. 4B) of mice infected with MHV-cCXCL9 as compared to
tissues isolated from MHV-CXCL9-infected (Figs. 4C, D). Within the
CNS, there were no differences in cellular tropism as viral antigenwas
detected within glial cells present in mice infected with MHV-CXCL9
(Fig. 4E) and MHV-cCXCL9 (Fig. 4F). Histologic examination of the
livers at day 7 p.i. revealed that RAG1−/− mice infected with MHV-
cCXCL9 contained numerous lesions characteristic of MHV-induced
hepatitis characterized by large conﬂuent areas of hepatocyte
necrosis with varying degrees of anisonuleosis and multinucleation
as well as apoptosis (Fig. 4H). In general, livers from RAG1 −/− mice
infected with MHV-CXCL9 exhibited fewer and, in general, smaller
lesions and less hepatic damage and reactive nucleomegaly (Fig. 4G).
NK cells are protective in response to MHV infection of the liver
CXCL9 has previously been shown to be chemotactic for NK cells
expressing CXCR3 (Arai et al., 2002; Kakimi et al., 2001a; Mahalingam
et al., 1999). To determine if the decrease in mortality and viral burden
reﬂected differences in the proﬁle of NK cell inﬁltration, ﬂow
cytometric analysis of mononuclear cells isolated from the brains
and livers of mice infected with either MHV-CXCL9 or MHV-cCXCL9
was performed. The results shown in Fig. 5A reveal similar levels of NK
cells inﬁltrating into the brains of mice infected with either MHV-
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viral-derived CXCL9 did not enhance accumulation of NK cells. NK cell
inﬁltration was increased (p≤0.05) within livers of MHV-CXCL9-
infected mice compared to MHV-cCXCL9 at day 3 p.i. and levels
remained elevated by day 5 p.i., although this difference was not
signiﬁcant (Fig. 5A). To further evaluate whether NK cells contributed
to host defense, NK cells were depleted from MHV-CXCL9-infected
mice through treatment with anti-asialo GM1 antisera (Triﬁlo et al.,
2004) that resulted in a signiﬁcant reduction (p≤0.001) in NK cells
present in both brain and liver (Fig. 5B). The absence of NK cells within
the livers, but not the brain, resulted in a signiﬁcant (p≤0.01) increase
in viral titers supporting earlier studies indicating that NK cells are
important in controlling viral replication in within the livers of MHV-
infected mice (Fig. 5C) (Walsh et al., 2007).
Infection of either CXCL9+/+ or CXCL9−/− mice with MHV-CXCL9 results
in protection from disease
We next infected wild type C57BL/6 (CXCL9+/+) mice with either
MHV-CXCL9 or MHV-cCXCL9 in order to assess the contributions of
virally-derived CXCL9 to host defense. As shown in Fig. 6A, infection of
wild type mice with MHV-cCXCL9 resulted in ∼80% survival of mice
out to day 21 p.i. while 100% of mice infected with MHV-CXCL9
survived the infection. Correspondingly, enhanced survival in MHV-Fig. 7. Viral infection of CXCL9−/− mice. (A) Morality curves for CXCL9−/− mice infected
i.c. with either 5000 PFU of MHV-CXCL9 or MHV-cCXCL9. Mice infected with MHV-
cCXCL9 exhibited increased mortality rates with ∼65% of infected mice dead by day 9
p.i. while 100% of MHV-CXCL9-infected mice remained alive until day 21 p.i. Data are
representative of two separate experiments with a minimum of 7 mice per
experimental group. (B) Viral titers are reduced (⁎p≤0.05) within the brains and
livers of CXCL9−/− mice infected with MHV-CXCL9 compared to MHV-cCXCL9 at days
3, 5, and 7 p.i. By day 12 p.i., CXCL9−/− mice infected with either MHV-CXCL9 or MHV-
cCXCL9 were able to reduce viral titers below detectable levels (∼100 PFU/g tissue)
within the brain and liver. Data are presented as average±SEM from two separate
experiments with a minimum of three mice per time point.
Fig. 6. Viral infection of wild type (CXCL9+/+) mice. (A) Morality curves for (CXCL9+/+)
mice infected i.c. with either 5000 PFU of MHV-CXCL9 or MHV-cCXCL9. Infection with
MHV-CXCL9 (n=6) resulted in 100% survival out to day 21 p.i. and 80% survival in MHV-
cCXCL9-infected mice (n=6). (B) Viral titers are reduced within the brains of MHV-
CXCL9-infectedmice at days 3 (p≤0.09) and 7 p.i. (p≤0.003) compared toMHV-cCXCL9-
infected mice. By day 12 p.i., mice infected with either virus had cleared viral titers
below level of detection (∼100 PFU/g tissue, not shown). Within the livers, mice
infected with MHV-CXCL9 had reduced viral titers (p≤0.01) compared to MHV-cCXCL9-
infected mice at day 3 p.i. yet mice infected with either virus had cleared virus below
the level of detection (BD) by day 7 p.i. Data are presented as average±SEM and
represent two independent experiments with a minimum of 3 mice per time point.CXCL9-infectedmicewas associatedwith accelerated reduction in viral
burdenwithin both brain and liver compared toMHV-cCXCL9-infected
animals (Fig. 6B). CXCL9−/−mice (Park et al., 2002) were infected with
MHV-CXCL9 to determine if CXCL9 derived from the viral genome
resulted inprotection fromdisease. As shown in Fig. 7A, i.c. inoculation
with MHV-CXCL9 resulted in 100% survival out to day 21 p.i. while
infection with MHV-cCXCL9 resulted in ∼65% survival. Correlating
with survival inMHV-CXCL9-infectedmicewas a pronounced ability to
control viral replication that coincided with accelerated reduction in
viral burden within both the brain and liver when compared to mice
infected with MHV-cCXCL9. Within the brains of mice infected with
MHV-CXCL9, there was a signiﬁcant (p≤0.005) reduction in viral titers
at days 3, 5, and 7 p.i. compared to MHV-cCXCL9-infected mice (Fig.
7B). Similarly, viral titers were signiﬁcantly (p≤0.005) reduced within
the livers of MHV-CXCL9-infected mice compared to MHV-cCXCL9-
infected mice at days 3 and 5 p.i. (Fig. 7B). However, it is important to
emphasize that by day 12 p.i. surviving CXCL9−/− mice infected with
MHV-cCXCL9 were ultimately able to reduce viral titers within both
the brain and livers to levels comparable with mice infected with
MHV-CXCL9 (Fig. 7B). Assessment of immune cell inﬁltration within
infected tissues revealed increased (p≤0.005) levels of both CD4+ and
CD8+ T cells present in the brains of MHV-CXCL9-infected CXCL9−/−
139M. Muse et al. / Virology 382 (2008) 132–144mice at days 3 and 7 p.i. compared to MHV-cCXCL9-infected mice yet
similar numbers of T cell susbsets were present by day 12 p.i. in mice
infected with either virus (Fig. 8A). Determination of T cell numbers
within the livers revealed nodifferences in levels of inﬁltrating CD4+or
CD8+ T cells in CXCL9−/− mice infected with either MHV-CXCL9 orFig. 8. T cell and NK cell inﬁltration into brains and livers of infected CXCL9−/−mice. CXCL9−/
inﬁltration into the brains and livers determined at indicated times p.i. (A) Infection with MH
in the brain at days 3 and 7 p.i. compared to mice infected with MHV-cCXCL9. By day 12 p.i
infected with either virus. (B) No differences were detected in either CD4+ or CD8+ T cell migr
time point examined. (C) NK cell inﬁltration was increased (⁎p≤0.05) within the brains of M
similar numbers of NK cells were present at days 7 and 12 p.i. in mice infected with either vir
with either MHV-CXCL9 of MHV-cCXCL9. Data are presented as average±SEM from two sepMHV-cCXCL9 at days 3, 7, and 12 p.i. (Fig. 8B). Inﬁltration of NK cells
into the brains was reduced (p≤0.05) in mice infected with MHV-
cCXCL9 compared to MHV-CXCL9-infected mice while there were no
differences inNK cell inﬁltrationwithin the livers ofmice infectedwith
either virus at any time point examined (Fig. 8C).−mice were infected i.c. with either MHV-CXCL9 or MHV-cCXCL9 and T cell and NK cell
V-CXCL9 resulted in accelerated (⁎p≤0.05) accumulation of both CD4+ and CD8+ T cells
. there was no difference in numbers of CD4+ or CD8+ T cells within the brains of mice
ation into the livers of mice infected with MHV-CXCL9 compared toMHV-cCXCL9 at any
HV-CXCL9-infected mice at day 3 p.i. compared to mice infected with MHV-cCXCL9 yet
us. No differences in NK cell inﬁltrationwithin the livers were detected in mice infected
arate experiments with a minimum of three mice per time point.
Fig. 9.Histopathology of brains from infected CXCL9−/− mice. Representative brain and sections from CXCL9−/− mice infected with either MHV-cCXCL9 or MHV-CXCL9 at day 7 p.i.
Brains from MHV-CXCL9-infected mice (C) exhibited large perivascular inﬁltrates (arrows) and meningeal inﬂammatory lesions (arrowheads) when compared to mice infected
with MHV-cCXCL9 (A). Staining for viral antigen revealed numerous infected cells within the hippocampus of MHV-cCXCL9-infected mice (B) compared to mice infected with
MHV-CXCL9 (D). Histology and antigen staining was performed for two separate experiments with 2 mice per group and a minimum of 6 sections per mouse examined. Panels A
and C, 40× magniﬁcation and panels B and D, 400× magniﬁcation.
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at day 7 p.i. demonstrated an overall increase in inﬂammatory cell
inﬁltration with leukocyte accumulation within the perivasculature
as well as meningeal inﬂammation (Fig. 9C) compared to mice
infected with MHV-cCXCL9 (Fig. 9A). Immunostaining for MHV in
the brains of MHV-CXCL9-infected mice supported the titer data
with far fewer cells staining positive for viral antigen (Fig. 9D) when
compared to the brains of MHV-cCXCL9-infected mice which had
extensive staining for virus (Fig. 9B). Examination of the spinal
cords of surviving mice indicated overall similar severity of white
matter damage in mice infected with either MHV-CXCL9 or MHV-
cCXCL9 (data not shown). Livers from mice infected with MHV-
CXCL9 at day 5 p.i. exhibited small and scattered foci of periportal
inﬂammation consisting mostly of lymphocytes and vascular
congestion (Fig. 10D). In contrast, MHV-cCXCL9 infection resulted
in a more pronounced and severe hepatitis with portal tracts
destroyed by a combination of necrotic hepatocytes, neutrophils,
and lymphocytes (Fig. 10A). In correlation with the viral titer data,
there was decreased viral antigen detected in the livers of CXCL9−/−
mice infected with MHV-CXCL9 (Figs. 10E, F) compared to MHV-
cCXCL9 (Figs. 10B, C) infection. In both experimental groups, viral
antigen was present in hepatocytes encircling areas of focally
necrotic regions although this was dramatically reduced within
MHV-CXCL9-infected mice. In addition, MHV-cCXCL9-infected mice
exhibited signiﬁcantly increased (p≤0.01) levels of serum alanine
transferase (sALT) within the blood compared to MHV-CXCL9-
infected mice, further supporting increased liver disease in MHV-
cCXCL9-infected mice (Fig. 10G).
Discussion
This study utilized a reverse genetics approach to insert the
chemokineCXCL9 coding sequence into the genomeofMHV in order to
characterize how CXCL9 may inﬂuence host defense and/or disease inresponse to MHV infection. The results presented support and extend
earlier studies demonstrating a role for CXCL9 in host defense in
response to MHV infection (Liu et al., 2001). In these experiments,
administration of blocking antibodies speciﬁc for CXCL9 to mice
infected with the neurotropic JHM strain of MHV (JHMV), resulted in
increased mortality that correlated with diminished T cell inﬁltration
into the CNS and correspondingly higher viral titers. The present study
demonstrated that infection of mice in which CXCL9 is genetically
silenced with the A59 strain of MHV, which is capable of replicating in
both brain and liver, results in rapid mortality presumably due to
inability to sufﬁciently control viral replication in target organs. CXCL9
is expressed in both brain and liver early following MHV-A9 infection
of both C57BL/6 and RAG1−/−mice emphasizing that this chemokine is
rapidly secreted in response to infection. However, infected RAG1−/−
mice displayed a similarmortality curve as infected CXCL9−/−mice and
theseﬁndings demonstrate the importance of inﬁltrating leukocytes in
controlling MHV replication within these tissues. Our ﬁndings high-
light a previously unappreciated role for CXCL9 in enhancing innate
immune responses as MHV-CXCL9 infection of RAG1−/−mice resulted
in prolonged survival that correlated with reduced viral titers in both
brain and liver when compared to RAG1−/− mice infected with MHV-
cCXCL9. Increased NK cell inﬁltration into the liver, but not the brain,
was observed inMHV-CXCL9-infectedmice compared tomice infected
with the controlMHV-cCXCL9 virus. Furthermore, depletionofNK cells
from MHV-CXCL9-infected RAG1−/− mice resulted in increased viral
titers within the livers, but not the brains, indicating that NK cells
contribute in controlling MHV replication within the liver but are
dispensable in host defense within the CNS. These ﬁndings support
earlier studies demonstrating an important role for NK cells in
controlling MHV replication within the liver (Walsh et al., 2007;
Walsh et al., 2008). These ﬁndings are also of interest as we have
previously determined that i.c. infection of RAG1−/− mice with a
recombinant MHV expressing CXCL10 (MHV-CXCL10) resulted in
increased survival accompanied by reduced viral titers that correlated
Fig. 10. Liver pathology following viral infection of CXCL9−/− mice. Livers from MHV-CXCL9-infected mice (D) displayed fewer foci of inﬂammation (arrowheads) while livers from
MHV-cCXCL9-infected mice (A) exhibited more severe hepatitis with concentric rings of necrotic hepatocytes mixed with a predominant lymphocyte and neutrophil inﬁltrate.
Histology was performed for two separate experiments with 2 mice per group and a minimum of 6 sections per mouse examined. Viral antigen was detected within hepatocytes
encircling hepatic lesions (arrowheads) of mice infected with either MHV-CXCL9 (E) or MHV-cCXCL9 (B). Infection resulted in viral antigen in hepatocytes encircling areas of focally
necrotic regions in MHV-CXCL9 (F) and MHV-cCXCL9 (C) infected mice. Immunostaining was performed for two separate experiments with a minimum of 2 mice per group with 6
sections per mouse examined. (G) sALT data are representative of 2 separate experiments and no fewer than 2 mice per group. Panels A, B, D, and E, 100× magniﬁcation; panels C and
F, 400× magniﬁcation.
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(Triﬁlo et al., 2004). Depletion of NK cells in MHV-CXCL10-infected
RAG1−/−mice resulted in increased viral burden in the brain indicating
that increased expression of CXCL10 within the CNS mice lacking a
functional adaptive immune response conferred protection via attrac-
tion of NK cells (Triﬁlo et al., 2004). These ﬁndings are also supported
by earlier studies by Mahalingam and colleagues (Mahalingam et al.,
1999) in which infection of athymic nude mice with recombinant
vaccinia viruses expressing either CXCL9 or CXCL10 resulted in
protection from disease that was mediated by IFN-γ production by
NK cells. In contrast, the data presented in this study highlights
functional differences with regards to CXCL9 expression and host
defense within the CNS of RAG1−/− mice infected with MHV withregards to NK cells. Although MHV-CXCL9-infected RAG1−/− mice
exhibited increased survival that correlated with a reduction in viral
titers within the brains, protection from CNS disease was not
associated with increased NK cell inﬁltration or IFN-γ production
and depletion of NK cells did not result in increased viral titers.
Therefore, these ﬁndings argue that protection mediated by inclusion
of CXCL9 into the MHV genome is separate from either attracting and/
or activating NK cells and suggest alternative mechanisms to control
viral replication. Whether viral-derived CXCL9 increases local type I
IFN expression within the CNS that is capable of dampening MHV
replication (Ireland et al., 2008) or mutes MHV receptor expression by
susceptible cells which limits the spread of virus remains to be
determined. Alternatively, it may also be possible that increased levels
142 M. Muse et al. / Virology 382 (2008) 132–144of CXCL9 may inhibit viral binding to target cells through binding to
heparin sulfate on the cell surface as Chen and colleagues (Chen et al.,
2006) have recently reported that CXCL10 interaction with heparin
sulfate inhibits Dengue virus from binding target cells.
Infection of C57BL/6 mice with MHV-CXCL9 resulted in increased
protection from disease that correlated with accelerated clearance of
virus from both brain and liver when compared to mice infected with
MHV-cCXCL9 and this most likely correlates with increased T cell
inﬁltration into target tissues in response to elevated CXCL9 produc-
tion from the virus. However, surviving mice infected with MHV-
cCXCL9were eventually able to clear virus below levels of detection. In
order to more accurately deﬁne mechanisms associated with CXCL9-
mediated protection, CXCL9−/− mice were infected with the recombi-
nant viruses. Infectionwith MHV-CXCL9 resulted in increased survival
associated with increased inﬁltration of both CD4+ and CD8+ T cells
into the CNS and a corresponding decrease in viral burden. These
ﬁndings are consistent with earlier studies from our laboratory
indicating that antibody targeting of CXCL9 following MHV infection
of the CNS resulted in increasedmortality as a result of decreased Tcell
accumulation within the CNS indicating CXCL9 can function in host
defense by attracting T cells into the CNS in response toMHV infection
(Liu et al., 2001). Correspondingly, increased mortality accompanied
by reduced T cell inﬁltration into the CNS was observed in CXCL9
deﬁcient mice infected with MHV-cCXCL9. However, it is important to
emphasize that MHV-cCXCL9 infection of CXCL9−/−mice did not result
in 100% mortality while infection with wild type MHV-A59 did kill
100% of mice. At this time, the underlying mechanisms responsible for
this difference are not deﬁned as infection of RAG1−/− with MHV-
cCXCL9 resulted in a similar mortality curve as MHV-A59. This
difference may relate to potentially reduced rate of spread/replication
of MHV-cCXCL9 within infected tissues compared to MHV-A59.
Nevertheless, we believe this doesn't diminish the strengths of the
model system employed nor detract from the importance of CXCL9 in
host defense following MHV infection. With regards to MHV-cCXCL9
infection of C57BL/6 and CXCL9−/− mice, increased survival supports
the possibility that other chemokines, notably CXCL10 and CCL5, are
likely to compensate and aid in attracting virus-speciﬁc T cells into the
CNS (Glass et al., 2004; Liu et al., 2001b). We do not believe that the
absence of CXCL9 impairs the generation of virus-speciﬁc T cells
followingMHV infection as similar numbers of T cells speciﬁc for MHV
are generated in either CXCL9−/− or CXCL9+/+ mice in response to
MHV infection (data not shown). Moreover, there were no detectable
differences in the ability of leukocytes to exit the microvasculature
and enter the parenchyma in CXCL9−/− mice infected with either
MHV-CXCL9 or MHV-cCXCL9 indicating that the absence of CXCL9 did
not affects positional migration of cells following migration to the
CNS. Therefore, we conclude that viral-derived CXCL9 aids in
protection from MHV-induced encephalitis by attracting CXCR3-
positive T cells to sites of infection. Park et al. (Park et al., 2002)
have reported increased susceptibility of CXCL9−/− mice to bacterial
infections and also suggest that CXCL9 expression serves to optimize
antibody production through facilitating interactions between lym-
pocytes and antigen presenting cells within secondary lymphatic
tissues. Although we did not examine MHV-speciﬁc antibody
production following infection of CXCL9−/− mice, we don't believe
that lack of CXCL9 expression altered a protective humoral response as
there was no viral recrudescence within spinal cords nor increase in
mortality during later stages of disease in mice infected with MHV-
which is associated with deﬁciencies in antibody production (Ramak-
rishna et al., 2002, 2003). Examination of spinal cords of mice infected
with eitherMHV-CXCL9 or MHV-cCXCL9 indicate no differences in the
severity of demyelination supporting earlier studies that CXCL9
expression does not signiﬁcantly inﬂuence white matter damage in
mice persistently infected with MHV (Liu et al., 2001b).
Previous studies have demonstrated that CXCL9 is associated with
protection in response to viral infection of the liver (Arai et al., 2002;Hokeness et al., 2007; Kakimi et al., 2001a, 2001b; Salazar-Mather et
al., 2000). Indeed, administration of blocking antibodies speciﬁc for
CXCL9 to mice infected with various hepatotropic viral pathogens
results in alterations in liver pathology that is associated with a
modulation in leukocyte recruitment and highlight the importance of
CXCL9 in attracting activated CXCR3-bearing inﬂammatory cells (Arai
et al., 2002; Hokeness et al., 2007; Kakimi et al., 2001a, 2001b; Salazar-
Mather et al., 2000). Through use of mice deﬁcient in CXCL9, our
studies support and extend these earlier observations and indicate an
important role for CXCL9 in promoting a protective response following
MHV infection of the liver. However, protection afforded by CXCL9was
not associated with any sustained increase in T cells or NK cells within
the livers indicating that CXCL9 exerts a protective effect independent
of enhanced recruitment of inﬂammatory cells. This ﬁnding is
consistent with an earlier report from our laboratory demonstrating
that infection of CXCL10−/−mice with MHV-CXCL10 results in reduced
viral titers within the livers and protection from hepatitis but is not
associated with increased T cell or NK cell inﬁltration (Walsh et al.,
2007). Signaling through NKG2D has been shown to participate in
control of JHMV replication within the livers yet the mechanisms e.g.
enhanced cytokine secretion and/or cytolytic activity by inﬂammatory
cells has yet to be deﬁned (Walsh et al., 2008). The mechanisms by
which both CXCL9 and CXCL10 promote a protective response in the
liver following MHV infection independent of enhancing immune cell
inﬁltration is the focus of ongoing investigations.
Materials and methods
Viruses and cells
All stocks of MHV-A59 mutants and recombinants were propa-
gated inmouse 17CL1 cells and plaque titrations were carried out with
mouse L2 cells. For the determination of single-step growth kinetics,
monolayers of 17CL1 cells (100 cm2) were inoculated with MHV-
CXCL9 or MHV-cCXCL9 at a multiplicity of 0.01 PFU per cell for 2 h at
37 °C with rocking every 15 min. Inocula were removed, monolayers
were thoroughly rinsed with 37 °C HBSS and media (DMEM, 10% FBS)
was replaced. Incubationwas continued at 37 °C and aliquots of media
were withdrawn at 1, 3, 6, 9, 12, 24 and 48 h post infection: infectious
titers were subsequently determined. All viral titer assays were
performed using DBT monolayers as previously described (Glass et al.,
2001).
Mice
Age-matched 5–7 week old C57BL/6 mice and RAG1−/− (H-2b
background) were purchased from the National Cancer Institute,
Bethesda, MD. In addition, CXCL9−/−mice (C57BL/6, H-2b background,
Park et al., 2002) were bred in the UCI vivarium and 5–7week oldmice
used for experiments. Following anesthetization by i.p. injection with
ketamine, mice were injected i.c. with virus (5000 PFU) suspended in
30 μl of sterile saline. Experiments for all animal studies described
have been reviewed and approved by an appropriate institutional
review committee.
Plasmid constructs
A transcription vector for the construction of a CXCL9-expressing
recombinant virus was derived from plasmid pMH54 (Kuo et al.,
2000). In brief, pMH54 contains the bacteriophage T7 RNA poly-
merase promoter and a cDNA copy of the 5′-most 0.5 kb of the MHV
genome fused to the 3′-most 8.6 kb of the MHV genome. The MHV
sequence corresponds exactly to that of wild-type MHV-A59, with
the exception that it encodes silent AvrII and AseI sites [introduced
into the S protein open reading frame (ORF)] and three additional
nucleotides that result in the creation of an Sse8387I restriction site
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nucleotide addition results in an up-regulation of subgenomic
mRNA4 synthesis for reasons that are not currently understood. For
construction of plasmid pMH54-CXCL9, the CXCL9 ORF was cloned
from cDNA derived from mouse brain mRNA obtained from an MHV-
infected mouse at day 7 post-infection (p.i.) using CXCL9-speciﬁc
primers. This construct (designated WT-CXCL9-1) was cloned into
Stratagene's pPCR-Script Amp SK (+) cloning vector (San Diego, CA)
and served as the template for the two PCR reactions that yielded i)
CXCL9-MHV [CXCL9 coding sequence (CDS)] and ii) cCXCL9-MHV
(inverted CXCL9 CDS with engineered stop codons). CXCL9-MHV and
cCXCL9-MHV were each ligated into the pPCR-Script cloning vector
and the resulting plasmid vectors were transformed into E. coli,
grown to high concentrations, and subsequently puriﬁed using
Midiprep Kits (Qiagen, Valencia CA). The inserts were released from
speciﬁc plasmid vectors by cutting with the Sse8387I and BspE1
restriction endonucleases and gel puriﬁed fragments subsequently
ligated into the pMH54 vector resulting in generation of pMH54-
CXCL9 (wild type CXCL9 construct containing CXCL9-MHV insert) and
pMH54-cCXCL9 (control construct containing inverted CXCL9 CDS
with stop codons) (Fig. 2A). These plasmids were transformed into E.
coli and puriﬁed plasmids pMH54/CXCL9 and pMH54/cCXCL9 were
linearized with PacI restriction endonuclease and served as the
templates for RNA synthesis.
RNA synthesis and viral recombination
RNA was synthesized from the linearized plasmids pMH54-CXCL9
and pMH54-cCXCL9 using a T7 RNA-polymerase based reverse
transcription kit (T7 mMessage mMachine, Ambion, Austin TX).
These RNAs, corresponding to the 5′ end of the MHV genome and
containing either the CXCL9 or cCXCL9 transgenic coding sequences,
were transfected into L2 cells that had already been infected with
MHV-Alb4 2 h prior. MHV-Alb4 is a strain featuring a 29aa deletion
in the N gene rendering the virus temperature-sensitive and
thermolabile at 39 °C (Kuo et al., 2000; Masters et al., 1994). These
infected and transfected cells were overlayed onto conﬂuent
monolayers of 17CL1 cells and progeny virus was collected at the
ﬁrst signs of cytopathic effects (usually within 24–48 h of overlay) in
the 17CL1 monolayers.
Screening and analysis of putative recombinants
Screening for recombinant viruses containing either the trans-
genic CXCL9 or cCXCL9 sequence was performed in several steps.
First, conﬂuent L2 cell monolayers were infected with various
dilutions of passage 1 progeny that was previously harvested from
the 17CL1 monolayers. Dilutions of passage 1 virus stocks were
incubated with the L2 monolayers for two hours (with shaking every
15 min) and after 2 h the supernatant was removed and the cells were
overlayed with a 50:50 mixture of 1.9% Nobel agar and 2X DMEM.
These monolayers were incubated at 39 °C for 2 days. At 39 °C non-
recombinant temperature sensitive MHV-Alb4 will form small
plaques (1–2 mm) whereas recombinant progeny are easily distin-
guished by a much larger (4–5 mm) plaque-size. Several putative
recombinant progeny plaques were isolated for each viral construct
and puriﬁed by two rounds of plaque titration. Monolayers of 17CL1
cells were infected with these putative recombinants and RNA was
puriﬁed from these infected monolayers at the ﬁrst signs of CPE using
Ultraspec reagent (Biotecx Laboratories, Houston TX). cDNAs were
synthesized from these RNAs and the targeted insertion-regions were
cloned and sequenced from each isolate. Progeny virus with the
correct nucleotide sequence were thereafter named MHV-CXCL9
(WT-CXCL9 sequence) and MHV-cCXCL9 (control/inverted CXCL9
sequence with stop-codons) and grown over two passages in
serum-free media.Mononuclear cell isolation and ﬂow cytometry
Immunophenotyping of the cellular inﬁltrate present within
either brains and livers of infected mice was accomplished by
homogenized isolated tissue and generating a single cell suspension
and characterizing by ﬂow cytometry. Cell suspensions were
transferred to 15-mL conical tubes and Percoll (Pharmacia, Uppsala,
Sweden) was added for a ﬁnal concentration of 30%. One milliliter of
70% Percoll was underlaid, and the cells were centrifuged at 1300×g
for 30 min at 4 °C. Cells were removed from the interface and washed
twice. Livers were diced with a razor blade and a single cell
suspension was layered over an equal volume of Lympholyte M
(Cedar Lane, Ontario, Canada) in a 15 mL conical tube and centrifuged
at 1250×g for 20 min at 4 °C. Cells were removed from the interface
and washed twice. FITC-conjugated rat anti-mouse NK1.1 (BD
PharMingen, San Diego, CA), FITC-conjugated rat anti-mouse CD8a
for CD8+ T cells (BD Pharmingen, San Diego, CA); APC-conjugated rat
anti-mouse CD4 (BD Pharmingen, San Diego, CA) for CD4+ T cells were
was used to immunophenotype inﬁltrating cells. As controls, isotype-
matched FITC and APC Abs were used. Cells were incubated with Abs
for 30 min at 4 °C, washed, and analyzed on a FACStar (BD
Biosciences, Mountain View, CA). Data are presented as the total
number of positive cells within the gated population of cells from the
isolated tissue.
NK cell depletion
RAG1−/− mice were infected with MHV-CXCL9 and treated with
0.5 mg of anti-asialo GM1 antisera (Wako Chemicals, Richmond,
VA) or sterile HBSS (control) by intraperitoneal (i.p.) injection on
days -1, 0, 1 and 3 p.i. and NK cell inﬁltration into brains and livers
determined.
Pathology and immunohistochemistry
Brains and livers were removed at day 5 p.i. and placed in 5 mL of
Formal-Fixx™ (ThermoShandon, Pittsburg, PA) overnight at room
temperature after which portions of tissuewere embedded in parafﬁn.
Distribution of viral antigen was determined by immunoperoxidase
staining (Vectastain-ABC kit; Vector Laboratories, Burlingame, CA)
using the anti-JHMVmAb J.3.3 speciﬁc for the carboxyl terminus of the
viral nucleocapsid protein as a primary antibody and horse anti-
mouse IgG secondary antibody (Vector Laboratories, Burlingame, CA)
(Walsh et al., 2007b). Serum alanine aminotransferase (sALT)
concentrations were determined by using Inﬁnity™ ALT (GPT) Liquid
Stable Reagent (Thermo, Noble Park, Victoria, Australia) according to
manufacturer's speciﬁcations.
ELISA
Assessment of CXCL9 in the supernatants of MHV-CXCL9- and
MHV-cCXCL9-infected cells was determined with mouse MIG (CXCL9)
ELISA kit (R&D Systems, Minneapolis, MN) according to manufacturer
speciﬁcations. The results are presented as pg/mL.
Statistical analysis
All data were analyzed by performing the Student's t-test using
Sigma-Stat 2.0 software. Values of p≤0.05 were considered
signiﬁcant.
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